Cochrane · systematic review · CD011064
Calcium channel blockers for people with chronic kidney disease requiring dialysis
Mugendi, GA, Mutua, FM, Natale, P, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
9
No studies
3
Included studies
NR
No studies 3 · 20%Ungraded 3 · 20%Very low 2 · 13.3%Low 7 · 46.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Dihydropyridine calcium channel blockers versus placebo/control in people with chronic kidney disease requiring dialysis
Population: people with CKD requiring dialysis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Predialysis systolic blood pressure Dihydropyridine calcium channel blockers vs placebo/control | no estimate extracted | 1 study · 39 participants | Low Downgraded: risk of bias, imprecision |
Predialysis diastolic blood pressure Dihydropyridine calcium channel blockers vs placebo/control | no estimate extracted | 2 studies · 76 participants | Low Downgraded: risk of bias, imprecision |
Cardiovascular death Dihydropyridine calcium channel blockers vs placebo/control | no estimate extracted | 3 studies · 124 participants | Ungraded |
Intradialytic hypotension Dihydropyridine calcium channel blockers vs placebo/control | RR 0.54 [0.25, 1.15] | 2 studies · 287 participants | Low Downgraded: risk of bias, imprecision |
Other side effects Dihydropyridine calcium channel blockers vs placebo/control | no estimate extracted | NR | No studies |
Dihydropyridine calcium channel blockers versus other antihypertensives in people with chronic kidney disease requiring dialysis
Population: people with CKD requiring dialysis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Predialysis systolic blood pressure Dihydropyridine calcium channel blockers vs other antihypertensives | no estimate extracted | 4 studies · 180 participants | Low Downgraded: risk of bias |
Predialysis diastolic blood pressure Dihydropyridine calcium channel blockers vs other antihypertensives | no estimate extracted | 4 studies · 180 participants | Low Downgraded: risk of bias |
Cardiovascular death Dihydropyridine calcium channel blockers vs other antihypertensives | no estimate extracted | 3 studies · 164 participants | Ungraded |
Intradialytic hypotension Dihydropyridine calcium channel blockers vs other antihypertensives | RR 2.88 [0.12, 68.79] | 1 study · 92 participants | Very low Downgraded: risk of bias, imprecision |
Other side effects Dihydropyridine calcium channel blockers vs other antihypertensives | no estimate extracted | NR | No studies |
Dihydropyridine versus non‐dihydropyridine calcium channel blockers in people with chronic kidney disease requiring dialysis
Population: people with CKD requiring dialysis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Predialysis systolic blood pressure Dihydropyridine vs non‐dihydropyridine calcium channel blockers | no estimate extracted | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Predialysis diastolic blood pressure Dihydropyridine vs non‐dihydropyridine calcium channel blockers | no estimate extracted | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Cardiovascular death Dihydropyridine vs non‐dihydropyridine calcium channel blockers | no estimate extracted | 1 study · 40 participants | Ungraded |
Intradialytic hypotension Dihydropyridine vs non‐dihydropyridine calcium channel blockers | no estimate extracted | NR | No studies |
Other side effects1,5 Dihydropyridine vs non‐dihydropyridine calcium channel blockers | RR 0.13 [0.01, 2.36] | 1 study · 40 participants | Very low Downgraded: risk of bias |